Top Articles

Back at it with an OG elevator pitch. If you’re new to this series, we take the term “elevator pitch” literally—putting CEOs of publicly traded companies in an actual elevator to see what they’re made of. Today, we’ve got Scott Eldridge, CEO of Military Metals Corp ($MILI.CN / $MILIF). What do you think? Solid pitch? Is it a buy? Disclaimer: Not financial advice. We do not currently own shares of Military Metals Corp but may buy or sell at any time. Military Metals is not a client, and we were not compensated for this.

Billionaire Dr. Frost bought 5 million shares of small-cap $VERU on the NASDAQ. This company is trying to knock Ozempic off its high horse by developing an even better weight-loss drug called Enobosarm. It’s like Ozempic, but you don’t lose your gainz (aka muscle). How convenient. They’re still in the early stages, but that’s exactly why we’re telling you now. As usual, this is not financial advice. $VERU is a client, so yeah—we’re biased. But that doesn’t discredit the opportunity here. $VERU is backed by major institutions, bullish independent analyst ratings, and it passes the VHLA bullshit test. We don’t currently hold a share position in $VERU, but we’re actively looking. We may buy or sell at any time in the open market. For full disclosure and clarity, head to the link in our bio for the full disclaimer.

Tariff exempt, trading at a fraction of its underlying value, big merger coming, and rivaling the 2024 NASDAQ top performer $APP. This is one small cap to watch. You heard it here first. Like usual not financial advice, $SYTA is a client, we don't own shares in $SYTA but we may buy or sell at any moment in the open market. Link in bio for our full disclaimer.

Billionaire Dr. Frost bought 5 million shares of small-cap $VERU on the NASDAQ. This company is trying to knock Ozempic off its high horse by developing an even better weight-loss drug called Enobosarm. It’s like Ozempic, but you don’t lose your gainz (aka muscle). How convenient. They’re still in the early stages, but that’s exactly why we’re telling you now. As usual, this is not financial advice. $VERU is a client, so yeah—we’re biased. But that doesn’t discredit the opportunity here. $VERU is backed by major institutions, bullish independent analyst ratings, and it passes the VHLA bullshit test. We don’t currently hold a share position in $VERU, but we’re actively looking. We may buy or sell at any time in the open market.